Physician profile
Gregory C Scott
NPI 1932195112
$17,504.10
in general payments reported to CMS, 2019-2025
67 companies · $3,294 in 2025
The $3,294 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,616 · 2020: $526 · 2021: $1,606 · 2022: $2,891 · 2023: $3,052 · 2024: $3,520 · 2025: $3,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,866.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,495.12 | 2019-2025 | Duopa, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,233.71 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $874.36 | 2019-2025 | Nuplazid |
| Pfizer INC. | $858.95 | 2023-2025 | |
| Ucb, INC. | $736.39 | 2019-2025 | Zilbrysq, Nayzilam, Rystiggo |
| Lilly USA, LLC | $729.55 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Biogen, INC. | $707.66 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Emd Serono, INC. | $688.40 | 2019-2025 | Mavenclad |
| Argenx US, INC. | $656.22 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $622.53 | 2019-2025 | Uplizna, Aimovig |
| Alexion Pharmaceuticals, INC. | $578.08 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $540.55 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $497.72 | 2019-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $482.86 | 2019-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $469.19 | 2021-2025 | Hyqvia, Gammagard |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.